1. Алешикова, О.И. Лучевые и молекулярно-биологические критерии оценки эффективности неоадъювантной химиотерапии местнораспрост-
раненного рака шейки матки (IIB–IIIB стадий) /О.И. Алешикова // Российский онкологический журнал. — 2007. — №3 — С. 21–25.
2. Бохман, Я.В. Руководство по онкогинекологии. — Л., 1989 — С.464, Кузнецов В.В., Лебедев А.И., Морхов К.Ю., Грицай А.Н., 2002 Практическая онкология
3. Давыдов, М.И. Злокачественные новообразования в России и странах СНГ в 2006 году. ГУ РОНЦ им. Н.Н.Блохина РАМН /М.И.Давыдов, Е.М. Аксель. — М.: Медицинское информационное агентство, 2007.
4. Девятченко, Т.Ф. Особенности локализации и диагностики рецидивов рака шейки матки /Т.Ф. Девятченко, Н С. Филатова, Н.А. Коротина и др. //Частные вопросы практической онкологии (Волгоград). — 1995. — Т.51, вып. 3. — С. 50–53.
5. Козаченко, В.П. Клиническая онкогинекология: Руководство для врачей /В.П. Козаченко. — М.: Медицина, 2005. — С. 374.
6. Корман, Д.Б. Основы противоопухолевой химиотерапии: Практическая медицина /Д.Б. Корман. — М., 2006. — С. 94.
7. Косников, А.Г. Выбор адекватного лечения больных раком шейки матки T1N0M0: Актуальные вопросы онкологии. Материалы Междунар. Симп. /А.Г. Косников, С.Б. Баранов, Д.Р. Зельдович и др. — С.-Пб, 1996. — С. 193–195.
8. Кузнецов, В.В. Рак шейки матки: Руководство для врачей «Клиническая онкология» /В.В. Кузнецов, В.В. Козаченко, А.И. Лебедев, К.Ю. Морхов, А.Н. Грицай. — М.: Медицина, 2005. — С. 101–154.
9. Кузнецов, В.В. Хирургия инвазивного рака шейки матки /В.В. Кузнецов, А.И. Лебедев, К.Ю. Морхов, А.Н. Грицай // Практическая онкология. — 2002. — Т. 3, № 3. — С. 178–182.
10. Максимов, С.Я. Комбинированное лечение рака шейки матки /С.Я. Максимов, К.Д. Гусейнов // Практическая онкология. — 2002. — Т. 3, № 3.
11. Переводчикова, Н.И. Руководство по химиотерапии опухолевых заболе-
ваний: Краткое руководство /Н.И. Переводчикова. — М., 2005. — С. 289.
12. Урманчеева, А.Ф. Антрациклины в лечении опухолей женских половых органов /А.Ф. Урманчеева, Е.А. Ульрих // Журнал современная Онкология. — Т. 07/4/2005.
13. Урманчеева, А.Ф. Эпидемиология и диагностика рака шейки матки /А.Ф. Урманчеева, В.М. Мерабишвили, С.А. Сельков и др.// / Журнал акушерства и женских болезней. — 2001. — Т. XLX., вып. 1. — С. 80–86.
14. Харитонова, Т.В. Возможности лекарственной терапии рака шейки матки /Т.В. Харитонова // Журнал современная Онкология. — Т. 07/3/2005.
15. Arseneau, J. A phase II trial of carboplatin squamosus cell carcinoma of the cervix: GOG study /J. Arseneau, J.A. Blessing, F.B. Stehman et al. // Invest new drugs. — 2006. — 4(2). — P. 187–91.
16. Baker, L., Boutsehs J., Alberts D. et al. Proc ASCO. — 1985. — 4. — P. 120.
17. Benedet, J.L. Carcinoma or the cervix uteri /J.L. Benedet, F. Odicino, P. Maisonneuve, U. Beller, W.T. Creasman et al. // Int Gynaecol Obstet. — 2003. — 83 (Supp l.1). — P. 41–78.
18. Benjapibal, M. A pilot phase II study of capecitabine plus cisplatin in the treatment or recurrent carcinoma of the cervix /M. Benjapibal, C. Thirapakawong, C. Leelaphatanadit et al. / Oncology. — 2007. — 72(1–2). — 33–8. Epub 2007 Nov 12.
19. Bensouda, Y. Phase II of capecitabine and cisplatin in advanced, persistent or recurrent carcinoma of the cervix /Y. Bensouda, H. Errihanni, H. Elghissassi et al. //J Clin Oncol. — 2008. — 26 (May 20 suppl.) — Abs. 5574.
20. Bloss, J.D. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamosus carcinoma of the cervix: Gynecologic Oncology Group study. /J.D. Bloss, J.A. Blessing, B.C. Behrens et al. //J Clin Oncol. — 2002. — 20(7). — P. 1832–7.
21. Bonomi, P. Randomized trial of three cisplatin dose schedules in squamosus cell carcinoma of the cervix: the Gynecologic Oncology Group study /P. Bonomi, J.A. Blessing, F.B. Stehman et al. // J Clin Oncol. — 1985. — 3. — P. 1079–85.
22. Bonomi, P. A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamosus cell carcinoma of the cervix: a GOG group study /P. Bonomi, J. Blessing, H. Ball / Gynecol Onco. — 1999. — 34(3). — P. 357–9.
23. Bosma, P.J. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilberts syndrome. /P.J. Bosma, J.R. Chowdhury, C. Bakker et al. /N Ehgl J Med. — 2003.
24. Bouzide, K. A phase II study of gemcitabine (G) and cisplatin (C) combination in the treatment of recurrent cervical squamous cell carcinoma (RCSCC) /K. Bouzide, H. Mahouf / /Proc Am Soc Clin Oncol. — 2003. — 22: A1900.
25. Brewer, C.A. Cisplatin plus gemcitabine in previously treated squamosus cell carcinoma of the cervix:phase II study of GOG / C.A. Brewer, J.A. Blessing, R.A. Nagourney et al. // Gynecol Oncol. — 2006. — 100(2). — P. 385–8.
26. Burnett, A.F. Phase II in patients with advanced, persistent or recurrent squamosus cell carcinoma of the cervix /A.F. Burnett, L.D. Roman, A.A. Garsia et al. //Gynecol Oncol. — 2000. — 76. — P. 63–6.
27. Cavin, S.J., Geisler Н. Gynecol Oncol. — 1978. — 6. — P. 256–60.
28. Cervellino, J.C. Cisplatin and ifosfamide in patients with advanced squamosus cell carcinoma of the uterine cervix.Phase II trial /J.C. Cervellino, C.E. Araujo, O. Sanchez et al. // Acta Oncol. — 1995. — 34(2). — P. 257–9.
29. Chitaparanux, J. Phase II clinical study of irinitecan and cisplatin at first-line chemotherapy in metastatic or recurrent cervical cancer /J. Chitaparanux, A. Tonusin et al. // Gynecol Oncol. — 2003. — 89. — P. 402–7.
30. Coleman, R.E. A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix /R.E. Coleman, J.M. Clarke, M.L. Slevin et al. // Cancer Chemother Pharmacol. — 1999. — 27(1). — P. 52–4.
31. Daghestani, A.N. Cervix carcinoma: treatment with combination with cisplatin and bleomycin /A.N. Daghestani, T.B. Hakes, G. Lynch // Gynecol Oncol. — 1999. — 16(3). — P. 334–9.
32. Duenas-Gonsalez, A. Weekly cisplatin\low dose gemcitabine combination for advanced and recurrent cervical carcinoma /A. Duenas-Gonsalez, L.M. Hinojosa-Garsia, C. Lopez-Graniel et al. //Am J Clin Oncol. — 2001. — 24(2). — P. 201–3.
33. Duenas-Gonsalez, A. A phase II study of gemcitabin and cisplatin combination as induction chemotherapy for untreated locally advanced cervical carcinoma / A. Duenas-Gonsalez, C. Lopez-Graniel, A. Gonsalez et al.//Ann oncol. — 2001. — 12(4). — P. 541–7.
34. Duenas-Gonzalez, A. Induction chemotherapy with gemcitabine and oxaliplatin for locally advanced cervical carcinoma /A. Duenas-Gonzalez, C. Lopez-Graniel, A. Gonzalez et al. // Am J Clin Oncol. — 2003 Feb. — 26(1). — P. 22–5.
35. Fioretti, P. The influence of anatomo-surgical stage, tumor size, histological type and lymph node status on the clinical outcome of patients with clinical FIGO stage IB-II cervical cancer /P. Fioretti, A.Gadduci, M.G. Fabrini et al. //Cancer J. — 1990. — Vol.3, N2. — P. 6.
36. Fracasso, P.M. Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study /P.M. Fracasso, J.A. Blessing, J. Wolf et al. ///Gynecol Oncol. — 2003 Jul. — 90(1). — P. 177–80.
37. Garin, A. Randomized phase II study of irinitecan or irininotecan in combination with ciplatinum or cisplatinum in first line in patients with metastatic squamosus cell carcinoma of the cervix /A. Garin, V.M. Moiseenko, A. Rosznak et al. //Proc ASCO 20. — 2001. — Abs. 826.
38. Jemal, A. et al. National cancer Institute, SEER Program 1995–2001. /A. Jemal et al. // CA Cancer J Clin. — 2006. — 56. — P. 106–130.
39. Goedbals, L. et al. Vinorelbine in combination with cisplatin in South African patients with advanced cervical carcinoma /L. Goedbals et al. // Proc ECCO. — 2002. — 10. — Abs. 919.
40. Goedhals, L. et al. Vinorelbine in combination with carboplatin in South African patients with advanced cervical carcinoma /L. Goedhals et al. / Proc ECCO. — 1999. — 10. — Abs. 919.
41. Goedhals, L. A phase II study of gemcitabine in advanced cervux carcinoma: final data /L. Goedhals, W.R. Bezwoda // 31st annual meeting of the ASCO. — 1195. — Abs. 819.
42. Greggi, S. Gemcitabine is ineffective in recurrent, preradiated cervical cancer /S. Greggi, G. D’Agostino, D. Smaniotto et al. // Gynecol oncol. — 2000. — 78. — P. 76–7.
43. Hainsworth, J.D. 3rd. Paclitaxel, Carboplatin and long-term continuous infusion of 5-fluorouracil in the treatment of advanced of advanced squamosus and other selected carcinomas: result of a phase II trial /J.D.3rd. Hainsworth, 3rd. H.A. Burris, A.A. Meluch et al. // Cancer. — 2001. — 92(3). — P. 642–9.
44. Hernandez, P. Gemcitabine activity in cervical cancer cell lines /P.Hernandez, P. Olivera, A. Duenaz-Gonsalez et al. // Cancer Chemother Pharmacol. — 2001. — 48. — P. 488–92.
45. Innocenti, F. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. /F. Innocenti, S.D. Undevia, L. Iyer et al. //J Clin Oncol. — 2004. — 22. — P. 1382–88.
46. Kaern, J. A phase II study of 5-fluorouracil/cisplatin treatment of reccurent cervical carcinoma: a phase II study with long-term follow-up /J. Kaern, C. Trope, V. Abeler et al.// Acta Oncol. — 2000. — 29(1). — P. 25–8.
47. Kaern, J. Cisplatin/5-fluorouracil treatment of reccurent cervical carcinoma:a phase II study with long-term follow-up /J. Kaern, C. Trope, K. Sundfoer et al. // Gynecol Oncol. — 2006. — 60(3). — P. 387–92.
48. Kesic, V. Management of cervical cancer /V. Kesic // Eur J Surg Oncol. — 2006. — 32(8). — P. 832–7; Cadron, I. Chemotherapy for recurrent cervical cancer /I. Cadron, T. Van Gorp, F.Amant, K. Leunen et al. // Gynecol Oncol. — 2007. — 107(1Suppl.1). — S113-89-73.
49. Kuo, D.Y. Oxaliplatin plus paclitaxel for recurrent and metastatic cervical cancer: New York Cancer Consortium Trial P5840. JCO./D.Y. Kuo, S.V. Blank, Kobrinsky et al. // ASCO Annual Meeting Proceedings PI. — 2007. — Vol. 25, N18S (June 20Suppl). — Abs. 5549.
50. Lhom me С., Vermorker J., Miskiewicz E. et al. Europ J Cancer. — 2000. — 36 (2). — P. 194–99.
51. Lira-Puerto, V. Phase II trial of carboplatin and iproplatin in cervical cancer /V. Lira-Puerto, A. Silva, M. Morris, R. Martines et al. // Cancer Chemotherapy Pharmacol. — 1991. — 28. — P. 391–6.
52. Long, H.J. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of uterine cervix: a GOG group study /H.J. Long, B.N. Bundy, Jr.E.C. Grendys et al.//J Clin Oncol. — 2005. — 23. — P. 4626–33.
53. Long, H.J. Management of metastatic cervical cancer: review of the literature/ H.J. Long // J Clin Oncol. — 2007. — 25. — P. 2966–74.
54. Look, K.Y. Phase II evaluation of capecitabine in refractory nonsquamosus cell carcinoma of the cervix: GOG study /K.Y. Look, J.A. Blessing, C.M. Michener et al. / Int J Gynecol Cancer. — 2008. — Jul-Aug; 18(4). — P. 773–8.
55. Lorvidhaya, V. Gemcitabine and cisplatin in patients with metastatic cervical cancer /V. Lorvidhaya, I. Chitaparanux et al. / ASCO. — 2000. — Abs. 1554.
56. Lorvidhaya, V. Gemcitabine and cisplatin in patients with metastatic cervical cancer /V. Lorvidhaya, Chitaparanux, P. Kamnerdsupaphon et al. //Gan To Kagaku Ryono. — 2004. — 31(7). — P. 1057–62.
57. Mahfouf, H. Gemcitabine and cisplatin in recurrent, advanced or metastatic cervical squamosus cell carcinoma /H. Mahfouf, K. Bouzid / ASCO. — 2001. — Abs. 824.
58. Matulonis, U. A phase I study of cisplatin and gemcitabine for recurrent cervix cancer following primary radiotherapy /U. Matulonis, S. Campos, M. Seiden et al. // ASCO. — 2000. — Abs. 1571.
59. Matulonis, U. Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer /U. Matulonis, S. Campos, L. Duska et al. / Gynecol Oncol. — 2006. — 103(1). — P. 160–4.
60. Moore, D.H. Phase III of cisplatin with or without paclitaxel in stage IVB, recurrent or persistent squamosus cell carcinoma of the cervix: a GOG group study /D.H. Moore, J.A. Blessing, R.P. McQuellon et al. // J Clin Oncol. — 2004. — 22. — P. 3113–9.
61. Moore, D.H. A randomized phase III study of cisplatin versus cisplatin plus paclitaxel in stage IV B, recurrent or persistent squamosus cell carcinoma of the cervix: A Gynecology Oncology Group study /D.H. Moore, R.P. McQellon, J.A. Blessing et al. // ASCO. — 2001. — Abs. 801.
62. Morris, M. Phase II study of cisplatin and vinorelbine in squamosus cell carcinoma of the cervix: GOG study. /M. Morris, J.A. Blessing, B.J.Monk et al. //J Clin Oncol. — 2004. — 22 (16). — P. 3340–4.
63. Muskato, M.S., Perry M.C., Yarbo J.N. Semin Oncol. — 1982. — 9. — P. 373–87.
64. Nagao, S. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. /S. Nagao, K. Fujiwara, T. Oda et al. /Gynecol Oncol. — 2005. — 96(3). — P. 805–9.
65. Nakano, E. How feasible the carboplatin and irinotecan combination therapy is for advanced or recurrent cervical cancer /E. Nakano, N. Katsumata, M. Yunokawa et al. // Medical Oncol Department National cancer center. — 2007.
66. Omura, G.A. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamosus cell carcinoma of the cervix:a GOG group study /G.A. Omura, J.A. Blessing et al. // J Clin Oncol. — 1997. — 15. — P. 165–71.
67. Owada, M. Phase II study of combination chemotherapy using irinitecan and nedaplatin for patients with primary advanced or recurrent cervical cancer /M. Owada, S. Machida, H. Fujiwara et al. //J Clin Oncol. — 2004. — ASCO Annual MeetingProceedings. — Vol. 22(14). — Abs. 5088.
68. Papadimitriou, C.A. Phase II trial of Paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix / C.A. Papadimitriou, K. Sarris, L.A. Moulopoulos et al. // J Clin Oncol. — 1999. — 17 (3). — P. 761–6.
69. Pectasides, D. Carboplatin and paclitaxel in metastatic or recurrent cervical cancer /D. Pectasides, Papaxoinis, E. Pectasides, N. Xiros et al. // Int J. Gynecol Cancer. — 2008.
70. Peters, G.H.Q. Interaction between cisplatin and gemcitabine in vitri and in vivo /G.H.Q. Peters, A.M. Bergman, V.W.T Ruin van Haperen et al. // Semin Oncol. — 1995. — 22 (Suppl 11). — P. 72–9.
71. Pignata, S. Phase II study of cisplatin and vinorelbine as fisrt-line chemotherapy in patients with carcinoma of uterine cervix. /S. Pignata, G. Silvestro, E. Ferrari et al. // J Clin Oncol. — 1999. — 17(3). — P. 756–60.
72. Piver, M.S. First-line therapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix — a phase II study /M.S. Piver, S.A. Ghamande, G.H. Eltabbakh et al. // Gynecol Oncol. — 1999. — 75(3). — P. 334–7.
73. Potter, M.E. Factors affecting the response of recurrent squamosus cell carcinoma of the cervix to cisplatin /M.E. Potter, K.D. Hatch, H.M. Shingleton, V.V. Baker // Cancer. — 2000. — 63(7). — P. 1283–6.
74. Rose, P.G. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamosus cell carcinoma of the cervix /P.G. Rose, J.A. Blessing, D.M. Gershenson et al. // J Clin Oncol. — 1999. — 19(9). — P. 2676–80.
75. Nori, S. A phase II study of irinotecan hydrochloride (CPT-11) and carboplatin (CBDCA) as palliative chemotherapy in patients with recurrent and metastatic cervical cancer /S. Nori, N. Katsumata, M. Andoh et al. // ASCO. — 2002. — Annual Meeting 21. — Abs. 835.
76. Schilder, R.J. Evaluation of gemcitabine in patients with squamosus cell carcinoma of the cervix: a phase II study GOG. /R.J. Schilder, J.A. Blessing, M. Morgan et al. //Gynecol Oncol. — 2000. — 76. — P. 204–7.
77. Stokes, Z. Phase I dose finding of capecitabine(Xeloda), radiotherapy and cisplatin in the treatment of locally advanced squamosus cervical cancer /Z. Stokes, P. Symonds, T. Habeshaw et al. // Gynecol Oncol. — 2005. — Jun; 97(3). — P 790–5.
78. Sugiyama, T. Combination therapy with CPT-11 and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer /T. Sugiyama, T. Nishida et al. /Brit J Cancer. — 1999. — P. 81.
79. Sutton, G.P., Blessing J.A., Adcock L. et al. Invest New drugs. — 1989. — 7. — P. 341–3.
80. Thiphen, T. Cis-platinum in treatment of advanced or recurrent squamosus cell carcinoma of the cervix:a phase II study of the Gynecologic Oncology Group /T. Thiphen, H. Shingleton, H. Homesley, L. Lagasse et al. //Cancer. — 1981. — 48. — P. 899–903.
81. Thiphen, T. The role of chemotherapy in the management of carcinoma of the cervix /T. Thiphen // Cancer J. — 2003. — 9. — P. 425–32.
82. Tinker, A.V. Carboplatin and paclitaxel for advancedc and recurrent cervical carcinoma: British Columbia Cancer Agency experience /A.V.Tinker, K. Bhagat, K.D. Swenerton et al. //Gynecol Oncol. — 2005. — 98(1). — P. 54–8.
83. Tsuda, H. Phase II of irinitecan (CPT-11) and nedaplatin with recombinant human granulocyte colony stimulating factor support in with advanced and recurrent cervical cancer /H. Tsuda, Y. Hashiguchi, S. Nishimura et al. // J Clin Oncol. — 2004. — ASCO Annual Meeting Proceedings. — Vol. 22(14). — Aab. 5065.
84. Umesaki, N. Combination chemotherapy with irinotecan (CPT-11) and mitimycin-c (MMC) for advanced or recurrent squamosus cell carcinoma of the cervix: Japanese Gyn Oncol Group study /N. Umesaki, T. Fujii et al. //ASCO. — 2003. — Abs. 1869.
85. Varia, M.A. Cervical carcinoma metastatic to para-aortic nodes:extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: GOG study / M.A. Varia, B.N. Bundy, G. Deppe et al. //Int J Radiant Oncol Biol Phys. — 1998. — 42(5). — P. 1015–23.
86. Weiss, G.R. A phase II trial of carboplatin for recurrent or metastatic squamosus carcinoma of the uterine cervix: Southwest Oncology Group study /G.R.Weiss, S. Green, E.V. Hannigan et al. // Gynecol Oncol. — 1990. — 39(3). — P. 332–6.
87. Zanetta, G. Paclitaxel, ifosfamid and cisplatin therapy for recurrent or advanced squamosus cell cervical cancer /G. Zanetta et al. // Proc ECCO. — 1999. — 10. — Abs. 905
|